Page 17 - Read Online

1998;27:1578-83. microcirculation after experimental hepatic arterial embolization:
19. Lewis AL, Taylor RR, Hall B, Gonzalez MV, Willis SL, Stratford comparison of different embolic agents. Radiology 1999;211:177-81.
PW. Pharmacokinetic and safety study of doxorubicin-eluting beads 38. Geschwind JF, Artemov D, Abraham S, Omdal D, Huncharek
in a porcine model of hepatic arterial embolization. J Vasc Interv MS, McGee C, Arepally A, Lambert D, Venbrux AC, Lund GB.
Radiol 2006;17:1335-43. Chemoembolization of liver tumor in a rabbit model: assessment of
20. Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, tumor cell death with diffusion-weighted MR imaging and histologic
Leppard SW, Wolfenden LC, Palmer RR, Stratford PW. DC bead: analysis. J Vasc Interv Radiol 2000;11:1245-55.
in vitro characterization of a drug-delivery device for transarterial 39. Shiina S, Tagawa K, Niwa Y, Unuma T, Komatsu Y, Yoshiura K,
chemoembolization. J Vasc Interv Radiol 2006;17:335-42. Hamada E, Takahashi M, Shiratori Y, Terano A, Omata M, Kawauchi
21. Tang Y, Taylor RR, Gonzalez MV, Lewis AL, Stratford PW. Evaluation N, Inoue H. Percutaneous ethanol injection therapy for hepatocellular
of irinotecan drug-eluting beads: a new drug-device combination carcinoma: results in 146 patients. AJR Am J Roentgenol
product for the chemoembolization of hepatic metastases. J Control 1993;160:1023-8.
Release 2006;116:e55-6. 40. Lencioni R, Bartolozzi C, Caramella D, Paolicchi A, Carrai M,
22. Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan Maltinti G, Capria A, Tafi A, Conte PF, Bevilacqua G. Treatment of
drug eluting beads for use in chemoembolization: in vitro and in vivo small hepatocellular carcinoma with percutaneous ethanol injection:
evaluation of drug release properties. Eur J Pharm Sci 2007;30:7-14. analysis of prognostic factors in 105 western patients. Cancer
23. Lewis AL, Gonzalez MV, Leppard SW, Brown JE, Stratford PW, 1995;76:1737-46.
Phillips GJ, Lloyd AW. Doxorubicin eluting beads - 1: effects of drug 41. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, Pompili
loading on bead characteristics and drug distribution. J Mater Sci M, Brunello F, Lazzaroni S, Torzilli G, Zucchi A. Hepatocellular
Mater Med 2007;18:1691-9. carcinoma and cirrhosis in 746 patients: long-term results of
24. Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y, percutaneous ethanol injection. Radiology 1995;197:101-8.
Kokudo N, Makuuchi M. Sequential preoperative arterial and portal 42. Hasegawa S, Yamasaki N, Hiwaki T, Sako K, Komorizono Y, Baba
venous embolizations in patients with hepatocellular carcinoma. Y, Imamura Y, Kubozono O, Yoshida A, Arima T. Factors that
Arch Surg 2004;139:766-74. predict intrahepatic recurrence of hepatocellular carcinoma in 81
25. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet patients initially treated by percutaneous ethanol injection. Cancer
2003;362:1907-17. 1999;86:1682-90.
26. Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat 43. Koda M, Murawaki Y, Mitsuda A, Ohyama K, Horie Y, Suou T,
Options Gastroenterol 2004;7:431-41. Kawasaki H, Ikawa S. Predictive factors for intrahepatic recurrence
27. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama after percutaneous ethanol injection therapy for small hepatocellular
Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y; Liver Cancer carcinoma. Cancer 2000;88:529-37.
Study Group of Japan. Prospective cohort study of transarterial 44. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa
chemoembolization for unresectable hepatocellular carcinoma in T, Koike Y, Yoshida H, Kawabe T, Omata M. A randomized
8510 patients. Gastroenterology 2006;131:461-9. controlled trial of radiofrequency ablation with ethanol injection for
28. Livraghi T, Meloni F, Morabito A, Vettori C. Multimodal image- small hepatocellular carcinoma. Gastroenterology 2005;129:122-30.
guided tailored therapy of early and intermediate hepatocellular 45. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency
carcinoma: long-term survival in the experience of a single radiologic ablation improves prognosis compared with ethanol injection
referral center. Liver Transpl 2004;10:S98-106. for hepatocellular carcinoma < or =4 cm. Gastroenterology
29. de Luis E, Bilbao JI, de Ciércoles JA, Martínez-Cuesta A, de 2004;127:1714-23.
Martino Rodríguez A, Lozano MD. In vivo evaluation of a new 46. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P,
embolic spherical particle (HepaSphere) in a kidney animal model. Crocetti L, Frings H, Laubenberger J, Zuber I, Blum HE, Bartolozzi
Cardiovasc Intervent Radiol 2008;31:367-76. C. Small hepatocellular carcinoma in cirrhosis: randomized
30. Guan YS, Liu Y. Interventional treatments for hepatocellular comparison of radio-frequency thermal ablation versus percutaneous
carcinoma. Hepatobiliary Pancreat Dis Int 2006;5:495-500. ethanol injection. Radiology 2003;228:235-40.
31. Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular 47. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review
carcinoma: where do we stand? Ann Surg Oncol 2010;17:1234-46. of randomized trials for hepatocellular carcinoma treated with
32. Kim JH, Yoon HK, Kim SY, Kim KM, Ko GY, Gwon DI, Sung KB. percutaneous ablation therapies. Hepatology 2009;49:453-9.
Transcatheter arterial chemoembolization vs. chemoinfusion for 48. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M.
unresectable hepatocellular carcinoma in patients with major portal Radiofrequency thermal ablation vs. percutaneous ethanol injection
vein thrombosis. Aliment Pharmacol Ther 2009;29:1291-8. for small hepatocellular carcinoma in cirrhosis: meta-analysis of
33. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, randomized controlled trials. Am J Gastroenterol 2009;104:514-24.
Mulcahy MF, Hunter RD, Nemcek AA Jr, Abecassis MM, Haines 49. Ohnishi K, Ohyama N, Ito S, Fujiwara K. Small hepatocellular
KG 3rd, Salem R. Yttrium-90 microspheres (TheraSphere) treatment carcinoma: treatment with US-guided intratumoral injection of acetic
of unresectable hepatocellular carcinoma: downstaging to resection, acid. Radiology 1994;193:747-52.
RFA and bridge to transplantation. J Surg Oncol 2006;94:572-86. 50. Ohnishi K. Comparison of percutaneous acetic acid injection and
34. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) percutaneous ethanol injection for small hepatocellular carcinoma.
for unresectable hepatocellular carcinoma: interim safety and survival Hepatogastroenterology 1998;45 Suppl 3:1254-8.
data on 65 patients. Liver Transpl 2004;10:S107-10. 51. Huo TI, Huang YH, Wu JC, Chiang JH, Lee PC, Chang FY, Lee
35. Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud SD. Sequential transarterial chemoembolization and percutaneous
M, Courtney A. Use of yttrium-90 glass microspheres (TheraSphere) acetic acid injection therapy versus repeated percutaneous acetic acid
for the treatment of unresectable hepatocellular carcinoma in patients injection for unresectable hepatocellular carcinoma: a prospective
with portal vein thrombosis. J Vasc Interv Radiol 2004;15:335-45. study. Ann Oncol 2003;14:1648-53.
36. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim 52. Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation
S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta and chemoembolization for hepatocellular carcinoma. Cancer J
R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. 2008;14:117-22.
Radioembolization for hepatocellular carcinoma using yttrium-90 53. Seidenfeld J, Korn A, Aronson N. Radiofrequency ablation of
microspheres: a comprehensive report of long-term outcomes. unresectable primary liver cancer. J Am Coll Surg 2002;194:813-28.
Gastroenterology 2010;138:52-64. 54. Yokoyama T, Egami K, Miyamoto M, Watanabe H, Hasegawa H,
37. Tancredi T, McCuskey PA, Kan Z, Wallace S. Changes in rat liver Iida S, Suzuki S, Nakamura Y, Okawa K, Hagiwara N, Takashima

8 Hepatoma Research | Volume 2 | Issue 1 | January 15, 2016